Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

A real-world cohort study finds that denosumab use is linked to a lower risk for incident knee osteoarthritis in adults with osteoporosis than the use of bisphosphonates.

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Please provide your email address to receive an email when new articles are posted on . Bisphosphonate use before denosumab discontinuation was associated with less bone mineral density loss among ...

Denosumab and bisphosphonates exhibit similar efficacy and safety profiles for preventing fractures among patients with osteoporosis. Evidence from a large population-based cohort study in South Korea ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

Based on the results of a non-inferiority study, in January 2018 the U.S. Food and Drug Administration (FDA) approved the use of denosumab for the prevention of skeletal events in patients with ...

A 52-year-old man with a history of metastatic renal cell carcinoma to the lungs presented with confusion and dehydration to the outpatient oncology department. The corrected-for-albumin serum calcium ...

During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia compared with 2.0% of those taking oral bisphosphonates, reported a group of largely FDA researchers ...

Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...